Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27425381 | 0.85 | ALDH1A1 (0.41) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL10520849 | 0.84 | HTR2A (0.39) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL11328208 | 0.81 | ALDH1A1 (0.38) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL1674533 | 0.79 | — | — | |
| SCHEMBL8040540 | 0.78 | TDP1 (0.41) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL27425379 | 0.78 | ALDH1A1 (0.46) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL9180639 | 0.78 | TRPV1 (0.41) | ALDH1A1TSHRTRPV1TRPA1 | |
| Hydrochloric Acid SCHEMBL11562089 | 0.77 | OPRM1 (0.46) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL272638 | 0.76 | ALDH1A1 (0.47) | HTR2AHRH1ALDH1A1TSHRTDP1 | |
| SCHEMBL13460472 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118055962-A | Epoxy curing agent composition comprising naphthol and naphthol derivative | 赢创运营有限公司 | 2024-05-17 | — | — | CN | claimed |
| EP-3420016-B1 | BENZYLATED MANNICH BASE CURING AGENTS, COMPOSITIONS, AND METHODS | EVONIK OPERATIONS GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-118055962-A | Epoxy curing agent composition comprising naphthol and naphthol derivative | 赢创运营有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-10669370-B2 | Benzylated mannich base curing agents, compositions, and methods | EVONIK OPERATIONS GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3420016-A1 | BENZYLATED MANNICH BASE CURING AGENTS, COMPOSITIONS, AND METHODS | Evonik Degussa GmbH (DE) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017147138-A1 | BENZYLATED MANNICH BASE CURING AGENTS, COMPOSITIONS, AND METHODS | EVONIK DEGUSSA GMBH (DE) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240691-A1 | BENZYLATED MANNICH BASE CURING AGENTS, COMPOSITIONS, AND METHODS | EVONIK OPERATIONS GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669370-B2 | Benzylated mannich base curing agents, compositions, and methods | H1-0, SRM, H1-2 | HTR2A 1661/4885HRH1 126/4885ALDH1A1 1296/4885 |
| US-20170240691-A1 | BENZYLATED MANNICH BASE CURING AGENTS, COMPOSITIONS, AND METHODS | H1-0, SRM, H1-2 | HTR2A 1661/4885HRH1 126/4885ALDH1A1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.